dm+d
411089001
Articles
Pemetrexed: Cytotoxic Drug Stability Monograph
12 March 2021Stability information is essential for the safe aseptic preparation of Pemetrexed.
Stability Study Report: Pemetrexed 2mg/ml and 13.5 mg/ml in 100ml NaCL 0.9% IV Infusion Bags
26 August 2020The purpose of the study was to investigate the chemical and physical stability of Pemetrexed (as the disodium salt) 2mg/mL and 13.5mg/mL in 100mL Sodium…
New Medicines
AlimtaNon-small cell lung cancer (NSCLC); with cisplatin + radioth 1st-line, followed by pem consolidation
Information
Alimta
Licence extension / variation
Eli Lilly
Eli Lilly
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Jun 15: Development discontinued [2].
Category
Dihydrofolate reductase inhibitor
In England and Wales 34,949 people were diagnosed with lung cancer in 2008. 85-90% are non-small-cell lung cancers (NSCLC). Approximately 45% of NSCLCs are squamous cell carcinoma, 45% are adenocarcinoma and 10% are large cell carcinoma. About 70% of NSCLC pts have stage IIIB or IV disease at presentation; 25% receive first-line chemotherapy & around 20-40% may receive second-line therapy [NICE scope].
Non-small cell lung cancer (NSCLC); with cisplatin + radioth 1st-line, followed by pem consolidation
Intravenous
Trial or other data
Oct 15: PIII NCT00686959 study has results. Median overall survival: Arm A Pemetrexed + Cisplatin and thoracic radiation therapy (TRT) 26.81 months (95% CI 20.40 to 30.92) vs. Arm B Etoposide + Cisplatin and TRT 24.97 months (22.18 to 29.83) [Hazard Ratio (HR) 0.98 (0.79 to 1.20); p=0.831] [1].